An early-stage investment fund supporting innovation across human health, food, agriculture, and climate, brings experience and expertise across both investing & operating in the Food and BioTech, ClimateTech and AgTech sectors. Its operating model allows access into the nearly 100 years of capability, ingenuity, manufacturing and distribution experience within Fonterra, while maintaining the agility and responsiveness to be a strong partner to start-ups and innovators in the space.
The firm typically invests in seed to Series A opportunities, though remains open to companies at later stages. The average check size ranges from $2M to $5M USD, with the ability to go beyond this. The fund is open to both leading and co-investing and will consider board positions on a case-by-case basis. The firm is actively seeking opportunities globally and is open to deal structures beyond equity investments, such as co-development and in-licensing, especially for technologies that align strategically with Fonterra.
The firm is generally interested in technologies that use nutrients to improve human health, such as those targeting the microbiome, cognitive function, sleep, and more. Areas of interest include the microbiome, alternative ingredients, and the application of molecules and proteins. The fund places a strong emphasis on data. In terms of development stages, the firm is open to working with companies from the pre-clinical stage through all phases of clinical and commercial development.
The firm does not have specific requirements for the company or management team. However, the fund seeks founding teams with passion and strong technical expertise.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment